Lazard Asset Management LLC Acquires 2,126 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Lazard Asset Management LLC raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating) by 110.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,043 shares of the company’s stock after buying an additional 2,126 shares during the period. Lazard Asset Management LLC’s holdings in Amphastar Pharmaceuticals were worth $140,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. US Bancorp DE lifted its stake in shares of Amphastar Pharmaceuticals by 49.5% in the second quarter. US Bancorp DE now owns 2,023 shares of the company’s stock valued at $70,000 after buying an additional 670 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at $74,000. Nisa Investment Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 22.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,550 shares of the company’s stock valued at $89,000 after buying an additional 460 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of Amphastar Pharmaceuticals by 114.4% in the first quarter. Captrust Financial Advisors now owns 2,770 shares of the company’s stock valued at $99,000 after buying an additional 1,478 shares in the last quarter. Finally, KBC Group NV bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $111,000. 63.11% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $28.40 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $19.21 and a 52-week high of $44.46. The company has a 50-day simple moving average of $28.99 and a 200 day simple moving average of $32.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.76. The company has a market capitalization of $1.37 billion, a PE ratio of 19.06 and a beta of 0.74.

Analysts Set New Price Targets

AMPH has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered shares of Amphastar Pharmaceuticals to a “buy” rating and set a $36.00 price target on the stock. in a research report on Friday, October 21st. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 25th. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Capital One Financial initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, July 29th. They set an “overweight” rating and a $44.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

About Amphastar Pharmaceuticals

(Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Further Reading

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.